JOJenna Oberg

Jenna Oberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jenna Oberg has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Antiphospholipid syndrome is a platelet factor 4–centric immunothrombotic disorder

    by Conroy O. Field, Amrita Sarkar, Khalil Bdeir, Hyunjun Kim, Santosh K. Yadav, Jenna Oberg, Guohua Zhou, Steven Jiang, Manas Gumedelli, Keith R. McCrae, et al.

    Antiphospholipid syndrome (APS) is an immunothrombotic disorder, frequently attributed to autoantibodies that bind β2-glycoprotein I (β2GPI). A study showed that the platelet-specific chemokine, platelet factor 4 (PF4), binds to β2GPI, enhancing recognition of β2GPI by APS antibodies. APS antibodies induce the release of neutrophil extracellular traps (NETs), webs of decondensed chromatin that bind both PF4 and β2GPI. We propose that PF4 bridges β2GPI to NETs (and other PF4-targeted polyanions), leading to the formation of prothrombotic PF4:β2GPI:NET immunotargets in APS. Dynamic light-scattering studies of isolated immunoglobulin G from 4 patients with triple-positive APS show formation of PF4:β2GPI:NET complexes that bind APS antibodies. NETs released in a microfluidic system bound β2GPI, but only in the presence of PF4, forming a multimolecular APS antigenic target. Whole blood infused through a photochemically injured, endothelium-lined microfluidic channel formed platelet-, fibrin-, and complement-rich thrombi that bound APS antibodies only in the presence of PF4. Thrombi were reduced in size if either ADAMTS13 or DNase I was infused. In a murine APS model, wild-type and transgenic mice expressing human PF4 (hPF4) ± FcγRIIA developed more intense neutrophil rolling along veins and more extensive thrombus formation after laser injury to cremaster arterioles and venules, whereas mice lacking PF4 did not. Three antigenically distinct anti-hPF4 monoclonal antibodies blocked thrombosis in vitro and neutrophil rolling and thrombosis in vivo. Our studies provide new insights into the basis of APS that has mechanistic parallels to other known PF4 immunothrombotic disorders and offer potential diagnostic and nonanticoagulant therapeutic strategies for clinical management.


  • Destabilization of PF4-antigenic complexes in heparin-induced thrombocytopenia

    by Lubica Rauova, Khalil Bdeir, Ann H. Rux, Manu Thomas Kalathottukaren, Jenna Oberg, Chanel C. La, David T. E. Lim, Vincent Hayes, Gavin T. Koma, Amrita Sarkar, et al.

    Heparin-induced thrombocytopenia (HIT) is initiated by antibodies that recognize large antigenic complexes composed of multiple molecules of cationic platelet factor 4 (PF4) and polyanions such as unfractionated heparin (UFH) that bind to each other primarily through electrostatic interactions. We asked whether the formation and stability of these HIT antigenic or ultralarge immune complexes (ULICs) would be inhibited by biocompatible synthetic polycationic molecules shown previously to dissociate UFH from antithrombin III and to inhibit polyphosphates. Members of this family of molecules, designated universal heparin reversal agents (UHRAs), inhibited formation and dissociated preformed ultralarge PF4-UFH (antigenic) complexes (ULCs), dissociated ULICs composed of the HIT-like monoclonal antibody KKO and ULCs, blocked binding of human HIT immunoglobulin G antibodies to PF4/heparin, binding of KKO to platelets, KKO-induced adhesion of platelets to activated human endothelium under flow, and microvascular thrombosis induced by KKO in a mouse model of HIT. These data suggest that UHRAs might provide a rationale intervention that acts at an early step in the pathogenesis of HIT to enhance the benefits and lessen the risks of nonheparin anticoagulants. Destabilization of immune complexes using polycationic inhibitors might also find a role in management of other polyanion PF4-antibody–mediated conditions, including vaccine-induced thrombocytopenia/thrombosis, postviral, and autoimmune HIT.